NBIX Price Prediction Next Week
Analysis and Insights
News Sentiment and Insider Activity:
Neurocrine Biosciences (NBIX) has recently announced a new share repurchase program, authorizing up to $500 million in buybacks, in addition to a previously announced $300 million program. This reflects a balanced approach to capital allocation, focusing on revenue growth through product investment, R&D advancement, and shareholder returns. However, there have been notable insider sales, with key executives selling shares in recent months, which could indicate a cautious outlook among insiders.
Technical Analysis:
NBIX is currently trading at $114.49, with key technical indicators suggesting a mixed outlook:
- RSI (14): 32.16, indicating oversold conditions.
- MACD: -5.98, showing bearish momentum.
- Fibonacci Levels: Resistance at $119.58 and support at $111.52.
Price Prediction and Recommendation:
Based on the oversold RSI and potential support from the share repurchase program, NBIX could experience a short-term rebound. The stock is expected to trade around $118 by the end of the next trading week.
Recommendation: Buy, with a target price of $118.00.
NBIX Similar Chart Price Prediction
The price of NBIX is predicted to go up -11.76%, based on the high correlation periods with APTO. The similarity of these two price pattern on the periods is 99.45%.
NBIX
APTO
Down: -11.76%Similarity: 99.45%
NBIX Revenue Forecast
NBIX EPS Forecast
NBIX FAQs
What is NBIX revenue forecast for next quarter？
What is NBIX eps forecast for next quarter？
NBIX Analyst's Forecast
Jeffrey Hung
Morgan Stanley
Buy
2025-03-07
Price Target
$185 → $150
Upside
+32.7%
Morgan Stanley assumed coverage of Neurocrine with an Overweight rating and a price target of $150, down from $185. The firm sees potential upside for Neurocrine shares with multiple commercial products, including Ingrezza and Crenessity, and late stage programs in schizophrenia and depression, the analyst tells investors.
Ashwani Verma
UBS
Strong Buy
2025-01-08
Price Target
$142 → $162
Upside
+16.79%
Carter Gould
Barclays
Buy
2024-12-23
Price Target
$160 → $165
Upside
+20.45%
